The first issue of the COVIRNA project newsletter is here!

View this email in your browser

COVIRNA is a patient-centred Innovation Action aiming to generate a diagnostic tool to identify COVID-19 patients at risk of developing fatal cardiovascular complications.

COVIRNA Project Newsletter Issue 1

Spread the word 👇

Forward

VIDEO | New video introduces the COVIRNA project to a wider audience

The official COVIRNA project video is now available. The video outlines the aim of the COVIRNA project to generate an innovative diagnostic tool to identify COVID-19 patients at risk of developing fatal cardiovascular complications in the context of the current pandemic, ultimately leading to their improved surveillance and care.

Please join us in sharing this video widely.

WATCH THE VIDEO →

Position paper from the EU-CardioRNA COST Action CA17129 | Cardiovascular RNA Markers and Artificial Intelligence May Improve COVID-19 Outcome

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of February 8th, 2020 and causing more than 2.3 million deaths according to the World Health Organization. Not only affecting the lungs and provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Continue reading →

DOWNLOAD THE PAPER →

Circulation paper from Andy Baker's group | Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells

A striking feature of severe forms of coronavirus disease 2019 (COVID-19), the current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is severe endothelial injury with micro- and macrothrombotic disease in the lung and other organs, including the heart. This has led to speculation that viral infection may damage the endothelium through 2 mechanisms: indirectly, via neighbourhood effects, circulating mediators, and immune mechanisms or directly by viral infection of endothelial cells (ECs). Continue reading →

DOWNLOAD THE PAPER →

FIMICS | Targeted quantification of cardiac enriched long non-coding RNAs

Within the COVIRNA project, apart from proposing a saliva diagnostic test EasyCOV, Firalis is proud to introduce FIMICS, an innovative tool to address cardiac impairment resulting from COVID since many reports are describing SARS-CoV-2 as targeting heart cells, especially cardiomyocytes inducing myocarditis and cardiac dysfunction in a significant number of deaths reported. The FIMICS kit is enabling the detection of 3233 cardiac-enriched lncRNAs jointly selected with the Luxembourg Institute of Health and partners to provide direct insight into the heart’s condition with only non-invasive blood samples. The innovation is designed to address cardiac disorders.

Read more here →

COVIRNA project in news

COST Action

News | EU-CardioRNA granted €3.88 million by the European Commission for COVID-19 research

The EU-CardioRNA (Catalyzing transcriptomics research in cardiovascular disease) COST Action has been awarded the COVIRNA project to improve surveillance and care of COVID-19 patients. The Action which is halfway through its four years, submitted a proposal with a consortium of 15 partners from healthcare, academia and industry from 12 European countries.

Read the full article here →

Annual Report 2020 | Rapid response for cardio COVID testing

Thanks to a COST Action network, a rapid diagnostic test for COVID-19 patients is being developed. The COVIRNA project is one of 23 research proposals selected under the Horizon 2020 call for 'Innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems'. The project was inspired by the successful and ongoing COST Action 'Catalyzing transcriptomics research in cardiovascular disease (EU-CardioRNA)'.

See page 24 of the report →

COVIRNA

News | Tackling COVID-19: The new EU-funded COVIRNA project

The COVIRNA project, led by the Luxembourg Institute of Health (LIH), is one of the 23 research projects awarded within the framework of the Horizon 2020 call for Expression of Interest “Innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems”. The project aims to foster the development of a novel diagnostic test to predict COVID-19 outcomes for patients and improve the cooperation between European research institutions to strengthen the response to the pandemic.

Read the full article here →

Visit our website

Like our page

The COVIRNA project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 101016072.

The content of this newsletter reflects only the COVRINA consortium’s views. The European Union is not liable for any use that may be made of the information contained herein.

This email was sent to <<Email Address>>
why did I get this? unsubscribe from this list update subscription preferences
COVIRNA · Rue Belliard · Brussel 1000 · Belgium